Committed Investment Partners Stand Behind Gamma Medica Inc.

Gamma Medica is currently offering potential investors the opportunity to participate in its Series B round of funding, which will be used not only to accelerate the commercialization phase of LumaGEM but to also further develop the product platform. The company is seeking an additional $20M of capital, with an additional $5M round of funding, Psilos Group Managers (“Psilos”) is leading the current round. To date, Psilos was the sole Series A Round investor, and continues to support the global commercialization of this technology.

Psilos, a healthcare investment firm focused on providing center and growth capital to companies operating in the healthcare economy has supported Gamma Medica since its inception. Founded in 1998, Psilos ( has $600 million under management and invests across three healthcare sectors: healthcare services, healthcare information technology, and medical technology. Funds managed by Psilos have successfully been invested in companies such as ActiveHealth, AngioScore, Definity Health, Extend Health, HealthEdge, PatientSafe Solutions, and SeeChange Health, among many others, which have played, and continue to play, key roles in the transformation of U.S. healthcare economy.

Inquires should be directed to:

Philip Croxford

President & Chief Executive Officer
12 Manor Parkway, Suite 3
Salem, NH 03079
Office: 603.952.4441